2019 Data DEA Policy 
NORML
APRIL 14, 2020
Federal law enforcement agents and their partners made fewer marijuana-related arrests in 2019, but seized a far greater number of plants than they did the year before, according to annual data compiled by US Drug Enforcement Administration. It was the second-lowest number of arrests reported by the DEA in the past decade.
SpeedWeed
MAY 11, 2021
Data recently released by the U.S. million marijuana plants in 2020, a figure that is up nearly 20% over 2019. The annual DEA report also shows that federal law enforcement officers made nearly 5,000 cannabis-related arrests in 2020, a year wracked by the social and economic fallout of the Covid-19 pandemic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
JULY 19, 2020
Drug Enforcement Agency (DEA) made far fewer cannabis-related arrests in 2019 than in previous years. Let’s take a closer look at what DEA data reveals. Per the DEA’s Domestic Cannabis Eradication/Suppression Program (DCESP) , a whopping 4,003,194 cannabis plants were seized and destroyed in 2019.
Canna Law Blog
JULY 26, 2023
I did my best to confirm Beau’s statement and was reminded of how challenging it has always been to aggregate data in this space. The study with 2017 data contains a disclaimer that “not all States reported data on the same basis.” Also, the 2017 data includes acreage for “approved” and not exclusively “cultivated”, hemp.
Cannabis Law Report
MAY 29, 2022
In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.
Cannabis Law Report
NOVEMBER 4, 2021
Should President Biden wish to acknowledge the political, economic, and moral realities surrounding cannabis policy, and fulfill the promises he made on the campaign trail, this report lays out a clear roadmap for how to do so.”. We’re beyond that.”. The FDA Director role continues to be unfilled.
The Blunt Truth
MARCH 10, 2020
The latter requires extensive vetting , including analyses of the underlying target condition and other related available treatments, conducting a cost benefit analysis from clinical data, as well as strategizing on how drug risks may be identified and mitigated. CBD Class Action Litigation.
Expert insights. Personalized for you.
286 
Let's personalize your content